Gaudium IVF and Women Health Ltd
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India.[1]
- Market Cap ₹ 838 Cr.
- Current Price ₹ 115
- High / Low ₹ 133 / 69.2
- Stock P/E 43.3
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 48.6 %
- ROE 52.2 %
- Face Value ₹ 5.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 55.4%
Cons
- Company has high debtors of 170 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 37 | 44 | 48 | 71 | |
| 23 | 24 | 28 | 42 | |
| Operating Profit | 14 | 20 | 19 | 29 |
| OPM % | 37% | 46% | 41% | 41% |
| 0 | 0 | 0 | 0 | |
| Interest | 1 | 0 | 1 | 2 |
| Depreciation | 1 | 1 | 2 | 2 |
| Profit before tax | 12 | 18 | 17 | 25 |
| Tax % | 26% | 26% | 38% | 25% |
| 9 | 14 | 10 | 19 | |
| EPS in Rs | 89.17 | 136.54 | 104.22 | 3.12 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 55% |
| Last Year: | 52% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 0.99 | 31 | 31 |
| Reserves | 8 | 22 | 26 | 16 | 28 |
| 6 | 12 | 17 | 21 | 24 | |
| 3 | 2 | 7 | 22 | 24 | |
| Total Liabilities | 18 | 37 | 51 | 89 | 107 |
| 4 | 18 | 19 | 18 | 30 | |
| CWIP | 0 | 0 | 0 | 7 | 0 |
| Investments | 0 | 0 | 0 | 5 | 5 |
| 14 | 18 | 32 | 58 | 72 | |
| Total Assets | 18 | 37 | 51 | 89 | 107 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -1 | 24 | 3 | 9 | |
| -1 | -16 | -5 | -15 | |
| 3 | 5 | -1 | 2 | |
| Net Cash Flow | 0 | 13 | -3 | -5 |
| Free Cash Flow | -2 | 9 | 1 | -0 |
| CFO/OP | 13% | 141% | 27% | 46% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 65 | 8 | 104 | 170 |
| Inventory Days | 29 | 111 | 168 | 175 |
| Days Payable | 114 | 77 | 62 | 338 |
| Cash Conversion Cycle | -20 | 41 | 210 | 7 |
| Working Capital Days | 61 | -52 | -15 | 44 |
| ROCE % | 76% | 45% | 49% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015
1d - NCLT New Delhi rejected Ramaa Capital's insolvency petition against Gaudium IVF; order dated May 15, received May 22, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Gaudium IVF schedules Q4 and FY26 earnings call for May 29, 2026 at 12:00 PM IST.
-
Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of The Audited Standalone And Consolidated Financial Statements/Results Of The Company For The Quarter And Year Ended March 31 2026.
2d - Board meeting on May 28, 2026 to approve audited Q4 and FY26 results; trading window closed.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - Monitoring Agency Report for quarter ended March 31, 2026; no deviation, Rs 8.69 crore utilised, Rs 81.31 crore unutilised.
-
Clarification On Price Movement
16 Apr - Company clarified price movement was market-driven and disclosed no new price-sensitive information.
Business Profile[1][2]
The company operates in the Assisted Reproductive Technology (ART) and IVF segment in India, following a hub-and-spoke model across 30+ locations (7 hubs and 28 spokes). It also runs a 15-bed day-care hospital in Janakpuri (Delhi NCR) and operates an in-house pharmacy through its wholly owned subsidiary, Gaudium International Pvt. Ltd.